Show simple item record

dc.contributor.authorKhamseh, ME
dc.contributor.authorEsteghamati, A
dc.contributor.authorNiafar, M
dc.contributor.authorAbbasi, D
dc.contributor.authorBeiki, MM
dc.date.accessioned2018-08-26T08:52:05Z
dc.date.available2018-08-26T08:52:05Z
dc.date.issued2018
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53620
dc.description.abstractTo explore glycemic control, and adverse events of Iranian people with uncontrolled type 2 diabetes after initiation of long-acting basal insulin, glargine. People with uncontrolled type 2 diabetes that was on at least two oral anti-diabetic drugs (OAD) were enrolled in this observational prospective study. Insulin glargine was prescribed by physicians in the course of routine clinical practice. Patients were followed for 24 weeks. Insulin doses were titrated to reach fasting blood sugar (FBS) target between 90 mg/dl and 130 mg/dl. HbA1c and adverse events were recorded at baseline, week 12, and week 24. Form a total of 292 participants, 243 patients completed the study. HbA1c, FBS, postprandial glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol, but not body mass index decreased during the study. The proportion of poorly controlled patients (HbA1C>9%) decreased from 172 (58.9%) to 39(13.4%), and 21(7.2%) during follow up. Controlled glycemia (HbA1C<7%) was detected in 7(2.4%), 48 (16.4%) and 56 (19.2%) of patients at baseline, week 12 and week 24. Hypoglycemia was reported in 5.1% and 3.4% of the participants in the week at 12 and 24, respectively. Patients felt more satisfied with their blood glucose control, timing and choices of meals, and hypo/hyperglycemic experiences. Insulin glargine initiation in people with uncontrolled type 2 diabetes on 2 OADs is associated with significant improvement in metabolic control. Insulin glargine has good safety profile and well tolerated by the patients. © 2018 Tehran University of Medical Sciences. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofActa Medica Iranica
dc.subjectglucose
dc.subjecthemoglobin A1c
dc.subjectinsulin glargine
dc.subjectlow density lipoprotein cholesterol
dc.subjectoral antidiabetic agent
dc.subjecttriacylglycerol
dc.subjectadult
dc.subjectArticle
dc.subjectblood glucose monitoring
dc.subjectbody mass
dc.subjectcholesterol blood level
dc.subjectclinical practice
dc.subjectfemale
dc.subjectglucose blood level
dc.subjectglycemic control
dc.subjecthuman
dc.subjecthypoglycemia
dc.subjectinsulin treatment
dc.subjectIranian people
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmetabolic regulation
dc.subjectmiddle aged
dc.subjectnon insulin dependent diabetes mellitus
dc.subjectobservational study
dc.subjectprospective study
dc.subjecttremor
dc.subjectweakness
dc.titleEarly insulin glargine initiation in iranian people with uncontrolled type 2 diabetes: Glycemic control, and adverse events
dc.typeArticle
dc.citation.volume56
dc.citation.issue4
dc.citation.spage249
dc.citation.epage254
dc.citation.indexScopus


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record